Effect of Olanzapine, Risperidone, and Haloperidol Treatment on Weight and Body Mass Index in First-Episode Schizophrenia Patients in India

INTRODUCTION: Like the increase of pro-inflammatory cytokines and oxidative stress as schizophrenia pathophysiology, haloperidol also increases RDW and MPV values. Both of these values have been clinicians concern because they are a risk factor for the various type of vascular disease. OBJECTIVE: This study aims to determine the side effect of haloperidol on RDW and MPV values in schizophrenic patients. METHODS: This research method uses observational analytic design with a prospective cohort approach with pre and posts analysis conducted at the Regional Special Hospital of South Sulawesi Province during May - July 2018 in 30 schizophrenic subjects. The subjects were diagnosed as first episode schizophrenia based on ICD 10, blood samples were taken, for RDW and MPV values before and after haloperidol was given at the 4th and 8th weeks. RESULTS: The results showed that the mean RDW value at the 4th week was higher in 15 mg/day haloperidol group (15.8) compared to 7.5 mg/day haloperidol group (15.3) with p<0.05. Mean RDW value taken at 8th week was higher in 15 mg/day haloperidol group (16.4) compared to 7.5 mg/day haloperidol group (15.6) with p<0.001. Mean MPV value taken at 8th week was higher in 15 mg/day haloperidol group (13.3) compared to 7.5 mg/day haloperidol group (11.6) with p<0.001. CONCLUSION: This study showed an increase in the RDW value in schizophrenia subjects prior to the haloperidol administration. RDW and MPV values were higher after haloperidol treatment compares to before haloperidol treatment. The increase of RDW and MPV values tend to be influenced by haloperidol dosage and administration duration.

Download Full-text

S201. HIPPOCAMPAL SUBFIELD VOLUMES AND CHANGE IN BODY MASS OVER 12 MONTHS OF TREATMENT IN FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDERS

Schizophrenia Bulletin ◽

10.1093/schbul/sbaa031.267 ◽

2020 ◽

Vol 46 (Supplement_1) ◽

pp. S114-S115

Author(s):

Stéfan Du Plessis ◽

Hilmar Luckhoff ◽

Sanja Kilian ◽

Laila Asmal ◽

Frederika Scheffler ◽

...

Keyword(s):

Substance Use ◽

Weight Gain ◽

Body Mass ◽

Interactive Effect ◽

First Episode ◽

Schizophrenia Spectrum Disorders ◽

Hippocampal Subfields ◽

Schizophrenia Spectrum ◽

Spectrum Disorders ◽

First Episode Schizophrenia

Abstract Background In this study, we explored the relationship between hippocampal subfield volumes and change in body mass over 12 months of treatment in 90 first-episode schizophrenia spectrum disorder patients (66 males, 24 females; mean age= 24.7±6.8 years). Methods Body mass index was assessed in patients at baseline, and at months 3, 6, 9 and 12. Hippocampal subfields of interest were assessed using a segmentation algorithm included in the FreeSurfer 6.0 software program. Results Linear regression analysis showed a significant interactive effect between sex and anterior hippocampus size as a predictor of change in body mass over 12 months, adjusting for age, substance use, treatment duration, and posterior hippocampal volumes. In an exploratory sub-analysis, partial correlations revealed a significant association between weight gain and smaller CA1, CA3 and subiculum volumes in females, but not males, adjusting for age and substance use, with similar trends evident for the CA4 and presubiculum subfields. Discussion In conclusion, our findings suggest that smaller anterior hippocampal subfields are associated with the development of weight gain over the course of treatment in first-episode schizophrenia spectrum disorders in a sex-specific fashion, and may partly explain the more severe and ongoing increase in body mass evident for female patients.

Download Full-text

Association Between Symptom Improvement and Change of Body Mass Index, Lipid Profile, and Leptin, Ghrelin, and Cholecystokinin Levels During 6-Week Olanzapine Treatment in Patients With First-Episode Psychosis

Journal of Clinical Psychopharmacology ◽

10.1097/jcp.0b013e3181f0580e ◽

2010 ◽

Vol 30 (5) ◽

pp. 636-638 ◽

Cited By ~ 5

Author(s):

Cengiz Basoglu ◽

Ozgur Oner ◽

Alpay M. Ates ◽

Ayhan Algul ◽

Umit Basar Semiz ◽

...

Keyword(s):

Body Mass Index ◽

Lipid Profile ◽

Body Mass ◽

First Episode Psychosis ◽

First Episode ◽

Symptom Improvement ◽

Olanzapine Treatment ◽

Episode Psychosis

Download Full-text

Poster #T68 BRAIN SYSTEMS REGULATING FOOD-INTAKE AND BODY MASS CHANGES DURING ACUTE ANTIPSYCHOTIC TREATMENT IN FIRST-EPISODE SCHIZOPHRENIA

Schizophrenia Research ◽

10.1016/s0920-9964(14)70885-0 ◽

2014 ◽

Vol 153 ◽

pp. S312

Author(s):

Robin Emsley ◽

Laila Asmal ◽

Bonginkosi Ciliza ◽

Stefan du Plessis ◽

Jonathan Carr ◽

...

Keyword(s):

Food Intake ◽

Body Mass ◽

First Episode ◽

Antipsychotic Treatment ◽

Body Mass Changes ◽

First Episode Schizophrenia

Download Full-text

Higher Body-Mass Index and Lower Gray Matter Volumes in First Episode of Psychosis

Frontiers in Psychiatry ◽

10.3389/fpsyt.2020.556759 ◽

2020 ◽

Vol 11 ◽

Author(s):

Marián Kolenič ◽

Filip Španiel ◽

Jaroslav Hlinka ◽

Martin Matějka ◽

Pavel Knytl ◽

...

Keyword(s):

Body Mass Index ◽

Body Mass ◽

Gray Matter ◽

First Episode ◽

Gray Matter Volumes

Download Full-text

Changes in Body Mass and Metabolic Profiles in Patients with First-Episode Schizophrenia Treated for 12 Months with A First-Generation Antipsychotic

European Psychiatry ◽

10.1016/j.eurpsy.2014.11.013 ◽

2015 ◽

Vol 30 (2) ◽

pp. 277-283 ◽

Cited By ~ 17

Author(s):

B. Chiliza ◽

L. Asmal ◽

P. Oosthuizen ◽

E. van Niekerk ◽

R. Erasmus ◽

...

Keyword(s):

Body Mass ◽

First Generation ◽

Fasting Blood Glucose ◽

First Episode ◽

Antipsychotic Treatment ◽

Metabolic Profiles ◽

Second Generation Antipsychotics ◽

Developing Communities ◽

Long Acting ◽

First Episode Schizophrenia

AbstractObjectives:To assess changes in body mass and metabolic profiles in patients with first-episode schizophrenia receiving standardised, assured treatment and to identify predictors and moderators of the effects.Methods:We investigated the changes in body mass, fasting blood glucose and lipids in 107 largely antipsychotic naïve, first-episode schizophrenia patients who were treated according to a standard algorithm with long-acting injectable flupenthixol decanoate over 12 months.Results:Eighty-three (78%) participants completed the 12 months of treatment, and 104 (97%) received 100% of the prescribed injections during their participation. There were significant increases in BMI (P < .0001), waist circumference (P = 0.0006) and triglycerides (P = 0.03) and decrease in HDL (P = 0.005), while systolic (P = 0.7) and diastolic blood pressure (P = 0.8), LDL (P = 0.1), cholesterol (P = 0.3), and glucose (P = 0.9) values did not change over time. The triglyceride: HDL ratio increased by 91%. Change in BMI was only correlated with change in triglycerides (P = .008). The only significant predictor of BMI increase was non-substance abuse (P = .002).Conclusions:The risks of weight gain and metabolic syndrome associated with antipsychotic treatment in first-episode schizophrenia are not restricted to second generation antipsychotics. This is a global problem, and developing communities may be particularly susceptible.

Download Full-text

Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study

Journal of Psychopharmacology ◽

10.1177/0269881118822173 ◽

2019 ◽

Vol 33 (3) ◽

pp. 284-294 ◽

Cited By ~ 10

Author(s):

Javier Vázquez-Bourgon ◽

Esther Setién-Suero ◽

Fuencisla Pilar-Cuéllar ◽

Rodrigo Romero-Jiménez ◽

Víctor Ortiz-García de la Foz ◽

...

Keyword(s):

Body Mass Index ◽

Body Mass ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Cannabis Use ◽

First Episode ◽

Low Density Lipoprotein Cholesterol ◽

Affective Psychosis ◽

Metabolic Alterations ◽

Cannabis Smoking

Background: Cannabis smoking is highly prevalent among patients with psychotic disorders. Its use has been found to be related to clinical characteristics and the prognosis of the disorder. Recent evidence indicates a protective effect of cannabis on weight gain and related metabolic alterations. However, there are no previous studies on the long-term longitudinal effects of cannabis on first-episode drug-naïve patients, which would thereby avoid the confounding effects of chronicity and previous treatment exposure. We aimed to explore the effect of cannabis smoking on weight and lipid/glycaemic metabolic measures in a sample of first-episode non-affective psychosis patients. Method: Anthropometric measurements and glycaemic and lipid parameters were obtained at baseline and three years after initiation of treatment. Patients self-reported their cannabis use at both time points. To explore the longitudinal effect of cannabis, patients were divided into three groups: continuers, discontinuers and non-users. Results: Cannabis users at baseline presented a lower weight ( F=14.85, p<0.001), body mass index ( F=13.14, p<0.001), total cholesterol ( F=4.85, p=0.028) and low-density lipoprotein-cholesterol ( F=6.26, p=0.013) compared to non-users. These differences were also observed after three years: weight ( F=8.07, p=0.005), body mass index ( F=4.66, p=0.032) and low-density lipoprotein-cholesterol ( F=3.91, p=0.049). Moreover, those patients discontinuing cannabis use presented a higher increase in weight ( F=2.98, p=0.052), body mass index ( F=2.73, p=0.067) and triglyceride-high-density lipoprotein ratio ( F=2.72, p=0.067) than the ‘non-users’ and ‘continuers’. Conclusions: The study suggests that cannabis use may produce a protective effect against weight gain and related metabolic alterations in psychosis. However, these results need to be replicated in a larger sample size.

Download Full-text

Weight Gain in First-Episode Psychosis

The Canadian Journal of Psychiatry ◽

10.1177/070674370304800412 ◽

2003 ◽

Vol 48 (4) ◽

pp. 272-276 ◽

Cited By ~ 29

Author(s):

Jean Addington ◽

Chrystal Mansley ◽

Donald Addington

Keyword(s):

Body Mass Index ◽

Weight Gain ◽

Body Mass ◽

First Episode Psychosis ◽

First Episode ◽

First Year ◽

Optimum Treatment ◽

Episode Psychosis ◽

Second Generation Antipsychotics ◽

Potential Weight

Objective: To examine the extent of weight gain in the first year of treatment in an early psychosis program. Method: Subjects were 114 individuals who had experienced a first episode of psychosis and had completed 1 year in a comprehensive first-episode program. Weight and body mass index were calculated on entry to the program and at 6 and 12 months. Most of the subjects were all being prescribed second-generation antipsychotics. Results: Significant increases in mean weight were observed in these young individuals over the course of the first year of treatment. Conclusions: If we are to work toward optimum treatment for first-episode subjects then potential weight gain needs to be addressed at the beginning of treatment and monitored during treatment.

Download Full-text